In parallel with the Phase 2b/3 LID development, an additional clinical program is planned that will evaluate dipraglurant for the treatment of dystonia patients.
Dystonia is a movement disorder that causes the muscles to contract and spasm involuntarily. Involuntary muscle contractions force the body into repetitive and often twisting movements as well as awkward, painful, irregular postures. There is presently no cure for dystonia. Many drugs are used to try to treat dystonia, including the leading treatment, botulinum toxin injections, but most patients are still left with significant symptoms.
Advancing dipraglurant into clinical development for dystonia is supported by in vivo data from multiple animal models (Bezard 2014; Sciamanna 2013).
An extended-release formulation (ER) has been developed for the treatment of dystonia that may confer more prolonged exposure to the drug.
We are currently collaborating with the Dystonia Medical Research Foundation to design and prepare the development of dipraglurant in dystonia as well as initiating an investigator led Phase II POC trial to explore dipraglurant’s therapeutic potential in dystonic patients.